メインコンテンツにスキップ

Dose Optimization Considerations for Targeted Radiation Therapies

The acquisitions of targeted radiation therapy companies (TRT) Point Biopharma by Eli Lilly and RayzeBio by Bristol Meyer Squibb have sparked investors’ interest in this therapeutic class. A growing number of companies are now developing TRTs, and GlobalData reports that venture capital deals in the field have grown 550% to $408 million in 2023.1 The … Continued

AIFA makeover: Italy’s leap into 2024

In a long-awaited development, Italy’s Medicines Agency, AIFA, underwent transformative changes on January 30th, 2024. This has been a recurrent topic of discussion, with talks of merging the Scientific Technical Advisory Committee (CTS) and the Price and Reimbursement Committee (CPR). However, the COVID-19 pandemic delayed these plans, leading to a continuous extension of the current … Continued

[Voice of Customer Article] Chinese CRO, Zhejiang Longcharm Biomedical Technology, Optimizes Sponsors’Non-clinical & Clinical Regulatory Review Processes with Pinnacle 21 Enterprise

Authors: Liming Fang, Emi Akatsu, Phillip Johnston Founded in 2016, Zhejiang Longcharm Biomedicine Technology Co., Ltd. provides one-stop R&D outsourcing services for the Chinese pharmaceutical industry. They can support BA/BE/PK clinical testing and data analysis services that comply with Chinese and American regulatory requirements for both novel and generic drug development programs. In 2023 July, … Continued

1 of 46
Powered by Translations.com GlobalLink OneLink Software